Generex (GNBT) Announces FDA Price Approval for Generex Oral-lyn in the Treatment IND Program
More News related to GNBT
- Mentor Capital Cancer Index Start Oversubscribed
- Generex Announces Participation in 2010 Arab Health Congress
- Generex Biotechnology Highlights OTC Product Line at The Vitamin, Diet & Sports Nutrition Efficient Program Planning Session
- Mentor Capital Takes Investment Position in Each of 10 Cancer Immunotherapy Index Companies
- Generex Makes Podium Presentation of Vaccine Technology Platform With Cancer & Influenza Updates at PepTalk 2010
More News related to FDA
- Isis Pharmaceuticals (ISIS) Falls On Safety Concerns
- AVANIR Pharma (AVNR) Gets New Patent for PBA Treatment Zenvia
- Curis (CRIS) Announces Publication of CUDC-101 Data
- Clarient (CLRT) Launches Lung Cancer Test Insight Dx Pulmotype
- Genzyme (GENZ) and Isis (ISIS) Said Mipomersen Phase 3 Study Meets Primary Endpoint
Generex Biotechnology Corporation (Nasdaq: GNBT) announced that the FDA has granted price approval in respect of the use of Generex Oral-lyn(TM) under the FDA's Treatment Investigational New Drug (IND) program.
Generex previously announced that the FDA has granted approval for the treatment use of Generex Oral-lyn(TM) in patients with Type 1 or Type 2 diabetes mellitus under the FDA's "Treatment IND" rules.
This latest FDA approval will permit the Company to charge for the product to recover costs.
Related Categories
FDAStocks Mentioned
+0.00Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
